The Radiopharmaceutical Blueprint 2026: 889 Organizations, Eight Layers, and the Year the Sector Was Repriced
Most maps of this industry start and stop at the companies developing a drug. This one counts the whole chain: 889 organizations across eight operational layers in 81 countries, from enriched feedstock to the radiopharmacy that hands a decaying dose to a patient. It then asks which layers are thin, and what the past twelve months of dealmaking says about where the value actually sits.
What this report answers
- Who is actually in the radiopharmaceutical industry, layer by layer, and where are they?
- Which layer of the chain is the narrowest relative to the demand on it?
- What did the two transactions of 3 August 2026 price, and what did they deliberately not price?
- Which organizations operate across four or more layers, and why are most of them state-owned?
- Which rules change under this sector in 2026 and 2027, and when do the comment periods close?
- Where does the workforce constraint now show up, and which roles clear at a premium?
- What happens to the sector's public visibility if the largest transaction closes on schedule?
- Which organizations sit between my finished dose and my patient, by name?
81 serving 185
contract manufacturers against developers - the ratio the report calls the single most important number in it, and the reason contract manufacture is named the narrowest point in the chain.
39 of 44
acquisitions recorded in and around the sector since August 2023 where the business bought was the layer around the drug rather than the drug itself. That share has risen in every year counted.
What the analysis establishes
The ecosystem, counted rather than illustrated
The first edition named roughly 130 companies chosen to make a point. This edition counts, and the count changes the picture. Organizations are placed in a layer by what they physically do rather than how they describe themselves to investors, and one that does two things is counted in both. The result is that the layer every market map opens with is not the largest, the two layers that physically build and physically deliver are together more than twice its size, and neither has a widely used public directory.
The year two transactions repriced the chain
Two deals were announced within hours of each other on 3 August 2026, taking opposite ends of the value chain off the public market in an afternoon. The chapter reads the contingent value right rather than the headline, on the argument that an earn-out is the most honest document in any transaction: it is the buyer stating in public which outcomes it is not yet willing to pay for. The full milestone schedule is reproduced, and it sits alongside a count of every acquisition in and around the sector since August 2023, split by whether the business bought was the drug or the apparatus around it.
Eight chapters, one per layer
Precursor and enrichment, isotope production, equipment and infrastructure, contract manufacture, developers and sponsors, specialist CRO and clinical, radiopharmacy and distribution, diagnostics and imaging. Each is counted, given its country distribution and its sub-segments, tested for where it is thin, and closed with what that means for the people an organization operating there will need to hire. The upstream layers are the ones where most participants are not primarily healthcare businesses at all, and compete internally for the same equipment and the same people.
Where the map is thin
Counting organizations tells you how many exist, not how much slack there is. The useful tests are the ratio between a layer and the layers depending on it, and the number of markets where a single organization is the only route to the patient. Seven chokepoints are named on that basis, each with its count and the reason it binds, and the fifteen organizations spanning four or more layers are set out with their layer footprint and home country. Most of them are state or quasi-state operators, which is its own finding about what vertical integration in this sector has historically required.
The rules moving underneath it
Three regulatory and reimbursement changes are in flight, two with comment periods still open as the report goes out. They cover medical-use licensing on the US side, the payment mechanics that decide whether a diagnostic agent is viable in a hospital outpatient setting, and the European quality guideline for this modality, unchanged since 2009. The chapter also records a year in which two major regulators reached opposite conclusions on the same molecule.
The constraint is people, and it is now in the inspection record
The workforce argument in this sector used to be an argument about hiring difficulty. In the past twelve months two regulators wrote it into enforcement, one of them suspending a manufacturing authorization with insufficient personnel to maintain GMP compliance among its recorded findings. The chapter sets the training pipeline against the demand estimate, quotes two chief executives describing the constraint in their own words, and states plainly which roles clear at a premium to the equivalent biologics role and which two sponsors routinely over-specify.
Five forecasts, and what would falsify each
Stated as forecasts rather than findings, each carrying the evidence it rests on and the observation that would show it was wrong. They cover the sector's public visibility, the timing of alpha isotope capacity against the readouts it has to serve, which layer consolidates next, the character of the next compliance failures, and where regulatory movement helps. The report invites readers to hold it to them in the next edition.
The roadmap, by the seat you are sitting in
The closing chapter is written four ways: for a company building a therapeutic, for a CDMO, CRO or service provider, for an investor or a board, and as a call to action for academia, government and industry bodies. Each is a short numbered list of things to do this quarter rather than a strategy. Behind it, Appendix A lists all 889 organizations by layer and country with a line on what each one does, which the report describes as both the section readers asked for most and the section most likely to contain a mistake about your organization.
How it was built
Built on the ProGen radiopharmaceutical ecosystem map: 889 organizations across eight layers, 7,115 clinical trial records drawn from four registry families, and every transaction in and around the sector since August 2023, maintained continuously and checked against primary sources to a research cutoff of 6 August 2026. Layer membership is an operational classification made by ProGen, not a self-description, and organizations active in more than one layer are counted in each. Where a figure is a company statement, an inference drawn across sources, or a classification made by ProGen, the text says so. Announced capacity is not treated as commissioned capacity, and nothing is converted into market size or patient numbers because the public evidence does not support that conversion. Chapter fourteen contains forecasts, stated as forecasts and paired with what would falsify them.
Written for people who have to make decisions with incomplete information: heads of technical operations placing a fill-finish contract, quality and regulatory leadership carrying an inspection, corporate development teams pricing a target, investors and deal desks testing a thesis, boards asking why a launch date moved, and anyone working out which organizations sit between their finished dose and their patient.
Contents
- The Ecosystem, Counted
- The Year the Sector Was Repriced
- L01 Precursor and Enrichment
- L02 Isotope Production
- L03 Equipment and Infrastructure
- L04 CDMO and Manufacturing
- L05 Developers and Sponsors
- L06 Specialist CRO and Clinical
- L07 Radiopharmacy and Distribution
- L08 Diagnostics and Imaging
- Where the Map Is Thin
- Regulation and Reimbursement
- The Constraint Is People
- Horizon: 2027 to 2029
- The Roadmap
- Appendix A: Directory of 889 Organizations
- Appendix B: Glossary
Organizations, agencies and bodies referenced (Appendix A names all 889)
Curium Pharma, Lantheus Holdings, BWXT Medical, Nordic Capital, Kinectrics, CapVest, Novartis, Advanced Accelerator Applications, Bayer, AstraZeneca, Fusion Pharmaceuticals, Bristol-Myers Squibb, RayzeBio, Telix Pharmaceuticals, Perspective Therapeutics, ARTBIO, Orano Med, Eckert & Ziegler, NorthStar Medical Radioisotopes, Nusano, TerraPower Isotopes, PanTera, SCK CEN, Cardinal Health, Jubilant Radiopharma, SOFIE Biosciences, PharmaLogic, RadioMedix, Ionetix, SpectronRx, Nucleus RadioPharma, OrbiMed, Alliance Medical, Canadian Nuclear Laboratories, ASP Isotopes, ARTMS, Board of Radiation and Isotope Technology, China Isotope & Radiation Corporation, NTP Radioisotopes, DuChemBio, Pars Isotope, UJV Rez, MURR, FDA, EMA, US Nuclear Regulatory Commission, Centers for Medicare & Medicaid Services, AIFA, Purdue University, Universite Laval
The full 119-page briefing is free. Tell us where to send it and it downloads immediately.
The State of Radiopharmaceuticals 2026
the systems-level operating-reality assessment of the global radiopharmaceutical sector. From $1,495.
See the full report →